Mark Lebwohl

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Dermatology, Immunology +14

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

Guidelines of care for the management of psoriasis and psoriatic arthritis

Alan Menter, Alice B. Gottlieb, Steven R. Feldman et al. · Journal of the American Academy of Dermatology · 2008 · 1.2K citations

Medicine, Dermatology, Internal Medicine +8

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

Gerald G. Krueger, John Koo, Mark Lebwohl et al. · PubMed · 2001 · 977 citations

Pharmacy, Dermatology, Health Sciences +15

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 831 citations

Medicine, Immunology, Pharmacotherapy +10